Company news

Rani Therapeutics Holdings, Inc. news in 2023

Rani Therapeutics Holdings, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

December 13, 2023

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

November 7, 2023

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Thir...

October 31, 2023

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

October 24, 2023

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

October 18, 2023

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

October 11, 2023

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

September 17, 2023

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

September 6, 2023

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

August 10, 2023

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

June 7, 2023

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

June 4, 2023

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 30, 2023

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 23, 2023

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

March 21, 2023

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

January 4, 2023

Calls in 2023

Decks in 2023